Cannabinoid receptors and neurodegenerative diseases

Riffat Tanveer, Niamh Mcguinness, Stephanie Daniel, Aoife Gowran, Veronica A. Campbell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Neurodegenerative disorders carry a significant social and economic burden, and the effective treatment of such illnesses remains a challenge for neuroscientists and neurologists. Although significant advances have been made on our understanding of the molecular mechanisms underlying neurodegenerative diseases, the translation of this knowledge into effective therapeutic treatments has been limited. There is still a dearth of curative treatments for most neurodegenerative disorders, with symptomatic relief being the principal target for drug action. Endocannabinoids belong to an evolutionary conserved neuro-signaling system and certain endogenous and exogenous components of this system are emerging as clinically promising neuroprotective agents due to their anti-oxidative, anti-excitotoxic, and anti-inflammatory properties. The cannabinoid system is, therefore, a potential target for several neurodegenerative conditions, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Research on the therapeutic potential of drugs that modulate endogenous cannabinoid tone is intense. Recent evidence implicates the endocannabinoid system as a potential pharmacological target to circumvent neurodegenerative disease pathology.

Original languageEnglish
Pages (from-to)633-639
Number of pages7
JournalWiley Interdisciplinary Reviews: Membrane Transport and Signaling
Volume1
Issue number5
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Cannabinoid Receptors
Neurodegenerative Diseases
Endocannabinoids
Cannabinoids
Therapeutic Human Experimentation
Translational Medical Research
Huntington Disease
Amyotrophic Lateral Sclerosis
Neuroprotective Agents
Therapeutics
Pharmaceutical Preparations
Parkinson Disease
Alzheimer Disease
Anti-Inflammatory Agents
Economics
Pharmacology
Pathology

ASJC Scopus subject areas

  • Biophysics
  • Cellular and Molecular Neuroscience

Cite this

Cannabinoid receptors and neurodegenerative diseases. / Tanveer, Riffat; Mcguinness, Niamh; Daniel, Stephanie; Gowran, Aoife; Campbell, Veronica A.

In: Wiley Interdisciplinary Reviews: Membrane Transport and Signaling, Vol. 1, No. 5, 09.2012, p. 633-639.

Research output: Contribution to journalArticle

Tanveer, Riffat ; Mcguinness, Niamh ; Daniel, Stephanie ; Gowran, Aoife ; Campbell, Veronica A. / Cannabinoid receptors and neurodegenerative diseases. In: Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 2012 ; Vol. 1, No. 5. pp. 633-639.
@article{471a95f9112d4123a22cf1adcca4d407,
title = "Cannabinoid receptors and neurodegenerative diseases",
abstract = "Neurodegenerative disorders carry a significant social and economic burden, and the effective treatment of such illnesses remains a challenge for neuroscientists and neurologists. Although significant advances have been made on our understanding of the molecular mechanisms underlying neurodegenerative diseases, the translation of this knowledge into effective therapeutic treatments has been limited. There is still a dearth of curative treatments for most neurodegenerative disorders, with symptomatic relief being the principal target for drug action. Endocannabinoids belong to an evolutionary conserved neuro-signaling system and certain endogenous and exogenous components of this system are emerging as clinically promising neuroprotective agents due to their anti-oxidative, anti-excitotoxic, and anti-inflammatory properties. The cannabinoid system is, therefore, a potential target for several neurodegenerative conditions, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Research on the therapeutic potential of drugs that modulate endogenous cannabinoid tone is intense. Recent evidence implicates the endocannabinoid system as a potential pharmacological target to circumvent neurodegenerative disease pathology.",
author = "Riffat Tanveer and Niamh Mcguinness and Stephanie Daniel and Aoife Gowran and Campbell, {Veronica A.}",
year = "2012",
month = "9",
doi = "10.1002/wmts.64",
language = "English",
volume = "1",
pages = "633--639",
journal = "Wiley Interdisciplinary Reviews: Membrane Transport and Signaling",
issn = "2190-460X",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - Cannabinoid receptors and neurodegenerative diseases

AU - Tanveer, Riffat

AU - Mcguinness, Niamh

AU - Daniel, Stephanie

AU - Gowran, Aoife

AU - Campbell, Veronica A.

PY - 2012/9

Y1 - 2012/9

N2 - Neurodegenerative disorders carry a significant social and economic burden, and the effective treatment of such illnesses remains a challenge for neuroscientists and neurologists. Although significant advances have been made on our understanding of the molecular mechanisms underlying neurodegenerative diseases, the translation of this knowledge into effective therapeutic treatments has been limited. There is still a dearth of curative treatments for most neurodegenerative disorders, with symptomatic relief being the principal target for drug action. Endocannabinoids belong to an evolutionary conserved neuro-signaling system and certain endogenous and exogenous components of this system are emerging as clinically promising neuroprotective agents due to their anti-oxidative, anti-excitotoxic, and anti-inflammatory properties. The cannabinoid system is, therefore, a potential target for several neurodegenerative conditions, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Research on the therapeutic potential of drugs that modulate endogenous cannabinoid tone is intense. Recent evidence implicates the endocannabinoid system as a potential pharmacological target to circumvent neurodegenerative disease pathology.

AB - Neurodegenerative disorders carry a significant social and economic burden, and the effective treatment of such illnesses remains a challenge for neuroscientists and neurologists. Although significant advances have been made on our understanding of the molecular mechanisms underlying neurodegenerative diseases, the translation of this knowledge into effective therapeutic treatments has been limited. There is still a dearth of curative treatments for most neurodegenerative disorders, with symptomatic relief being the principal target for drug action. Endocannabinoids belong to an evolutionary conserved neuro-signaling system and certain endogenous and exogenous components of this system are emerging as clinically promising neuroprotective agents due to their anti-oxidative, anti-excitotoxic, and anti-inflammatory properties. The cannabinoid system is, therefore, a potential target for several neurodegenerative conditions, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Research on the therapeutic potential of drugs that modulate endogenous cannabinoid tone is intense. Recent evidence implicates the endocannabinoid system as a potential pharmacological target to circumvent neurodegenerative disease pathology.

UR - http://www.scopus.com/inward/record.url?scp=84879192107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879192107&partnerID=8YFLogxK

U2 - 10.1002/wmts.64

DO - 10.1002/wmts.64

M3 - Article

VL - 1

SP - 633

EP - 639

JO - Wiley Interdisciplinary Reviews: Membrane Transport and Signaling

JF - Wiley Interdisciplinary Reviews: Membrane Transport and Signaling

SN - 2190-460X

IS - 5

ER -